Please login to the form below

Not currently logged in
Email:
Password:

Crisaborole

This page shows the latest Crisaborole news and features for those working in and with pharma, biotech and healthcare.

Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout

Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout

PDE 4 inhibitors are already used to treat inflammatory diseases in the lungs and skin, such as Amgen’s Otezla (apremilast) for psoriasis and Pfizer’s Eucrisa (crisaborole) for atopic dermatitis.

Latest news

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    Crisaborole is currently under FDA review. Late stage deals are not, however, a complete panacea. ... Corporate acquisition. Acquisition for $99.25 per share [55% premium], includes crisaborole under FDA review for mild to moderate eczema; est peak sales

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

AI and genomics: a revolution in drug discovery and development
...
Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....

Infographics